Recombinant multi-species CYP2E1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CYP2E1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is induced by ethanol, the diabetic state, and starvation. The enzyme metabolizes both endogenous substrates, such as ethanol, acetone, and acetal, as well as exogenous substrates including benzene, carbon tetrachloride, ethylene glycol, and nitrosamines which are premutagens found in cigarette smoke. Due to its many substrates, this enzyme may be involved in such varied processes as gluconeogenesis, hepatic cirrhosis, diabetes, and cancer. [provided by RefSeq, Jul 2008]
The Alternative Names of target: CYP2E1,Cytochrome P450 2E1,4-nitrophenol 2-hydroxylase, CYPIIE1, Cytochrome P450-J,CPE1,CYP2E,P450-J,P450C2E

Target products collectionGo to CYP2E1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0139-Ab-1/ GM-Tg-hg-SE0139-Ab-2 Human CYP2E1 protein Human
GM-Tg-rg-SE0139-Ab-1/ GM-Tg-rg-SE0139-Ab-2 Rat CYP2E1 protein Rat
GM-Tg-mg-SE0139-Ab-1/ GM-Tg-mg-SE0139-Ab-2 Mouse CYP2E1 protein Mouse
GM-Tg-cynog-SE0139-Ab-1/ GM-Tg-cynog-SE0139-Ab-2 Cynomolgus/Rhesus macaque CYP2E1 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0139-Ab-1/ GM-Tg-felg-SE0139-Ab-2 Feline CYP2E1 protein Feline
GM-Tg-cang-SE0139-Ab-1/ GM-Tg-cang-SE0139-Ab-2 Canine CYP2E1 protein Canine
GM-Tg-bovg-SE0139-Ab-1/ GM-Tg-bovg-SE0139-Ab-2 Bovine CYP2E1 protein Bovine
GM-Tg-equg-SE0139-Ab-1/ GM-Tg-equg-SE0139-Ab-2 Equine CYP2E1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0139-Ab-1/ GM-Tg-hg-SE0139-Ab-2; GM-Tg-rg-SE0139-Ab-1/ GM-Tg-rg-SE0139-Ab-2;
GM-Tg-mg-SE0139-Ab-1/ GM-Tg-mg-SE0139-Ab-2; GM-Tg-cynog-SE0139-Ab-1/ GM-Tg-cynog-SE0139-Ab-2;
GM-Tg-felg-SE0139-Ab-1/ GM-Tg-felg-SE0139-Ab-2; GM-Tg-cang-SE0139-Ab-1/ GM-Tg-cang-SE0139-Ab-2;
GM-Tg-bovg-SE0139-Ab-1/ GM-Tg-bovg-SE0139-Ab-2; GM-Tg-equg-SE0139-Ab-1/ GM-Tg-equg-SE0139-Ab-2
Products Name CYP2E1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name CYP2E1
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CYP2E1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.